EMA: Lentiviral thalassemia treatment on hold pending cancer investigation – Regulatory Focus

EMA: Lentiviral thalassemia treatment on hold pending cancer investigation | RAPS

press release, the agency related that bluebird bios actions came after a recipient of the related bb1111 gene therapy for sickle cell disease developed acute myeloid leukemia (AML). Another bb1111 recipient has also developed myelodysplastic syndrome (MDS), according to bluebird bio." />

See original here:

EMA: Lentiviral thalassemia treatment on hold pending cancer investigation - Regulatory Focus